Yondelis
What Yondelis is used for
Yondelis is indicated for the treatment of patients with advanced soft-tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients. Yondelis in combination with pegylated liposomal doxorubicin (PLD) is indicated for the treatment of patients with relapsed platinum-sensitive ovarian cancer.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Yondelis
- Active substance
- trabectedin
- Disease area
- Ovarian Neoplasms; Sarcoma
- Medicine group
- Antineoplastic agents
- ATC code
- L01CX01
- Marketing authorisation holder
- Pharma Mar S.A.
- Authorised in the EU since
- 2007
Official information
In the USA
In India
- Trabectedin: 1 brand in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Yondelis used for?
Yondelis is indicated for the treatment of patients with advanced soft-tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients. Yondelis in combination with pegylated liposomal doxorubicin (PLD) is indicated for the treatment of patients with relapsed platinum-sensitive ovarian cancer.
What is the active substance in Yondelis?
Yondelis contains trabectedin.
Who makes Yondelis?
The EU marketing authorisation holder is Pharma Mar S.A..
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU